29124-62-7

Usage

Uses

Used in Pharmaceutical Industry:
N-(4-bromo-2-trifluoromethl-pheny)-Acetamide is used as an intermediate in the synthesis of pharmaceutical drugs for its ability to contribute to the development of medications that address pain and inflammation. Its unique chemical structure allows it to be a key component in the formulation of effective treatments.
Used in Organic Synthesis:
In the realm of organic synthesis, N-(4-bromo-2-trifluoromethl-pheny)-Acetamide serves as a valuable intermediate, facilitating the creation of a range of organic compounds. Its presence in the synthesis process is crucial for the production of various organic materials that may have applications beyond the pharmaceutical sector.
Overall, N-(4-bromo-2-trifluoromethl-pheny)-Acetamide is a significant compound in the pharmaceutical and organic synthesis industries, playing a critical role in the development and production of a variety of important products.

Upstream product

• 445-02-3 4-bromo-2-trifluoromethyl-aniline 
• 103-88-8 4-bromoacetanilide 
• 344-62-7 N-[2-(trifluoromethyl)phenyl]acetamide 
• 2926-29-6 Langlois reagent 
• 75-36-5 acetyl chloride 

Downstream Products

• 400610-45-9 1-(4-bromo-2-trifluoromethyl-phenyl)-5-methyl-1H-tetrazole 
• 672961-18-1 N-[4-(4'-pyridyl)-2-trifluoromethylphenyl]acetamide 
• 1326310-54-6 4-cyclopropyl-2-nitro-6-(trifluoromethyl)aniline 
• 1326310-55-7 5-cyclopropyl-3-(trifluoromethyl)-1,2-benzenediamine 
• 157026-18-1 4-bromo-2-nitro-6-trilfuoromethyl-phenylamine 
• 157026-19-2 5-bromo-3-(trifluoromethyl)-1,2-benzenediamine 
• 179062-00-1 N-(4-bromo-2-nitro-6-trifluoromethyl-phenyl)-acetamide 

Relevant academic research and scientific papers

Triptycenyl Sulfide: A Practical and Active Catalyst for Electrophilic Aromatic Halogenation Using N-Halosuccinimides

A Lewis base catalyst Trip-SMe (Trip = triptycenyl) for electrophilic aromatic halogenation using N-halosuccinimides (NXS) is introduced. In the presence of an appropriate activator (as a noncoordinating-anion source), a series of unactivated aromatic compounds were halogenated at ambient temperature using NXS. This catalytic system was applicable to transformations that are currently unachievable except for the use of Br2 or Cl2: e.g., multihalogenation of naphthalene, regioselective bromination of BINOL, etc. Controlled experiments revealed that the triptycenyl substituent exerts a crucial role for the catalytic activity, and kinetic experiments implied the occurrence of a sulfonium salt [Trip-S(Me)Br][SbF6] as an active species. Compared to simple dialkyl sulfides, Trip-SMe exhibited a significant charge-separated ion pair character within the halonium complex whose structural information was obtained by the single-crystal X-ray analysis. A preliminary computational study disclosed that the πsystem of the triptycenyl functionality is a key motif to consolidate the enhancement of electrophilicity.

Visible-light-induced Pd-catalyzed: Ortho -trifluoromethylation of acetanilides with CF3SO2Na under ambient conditions in the absence of an external photocatalyst

A visible-light-induced Pd-catalyzed ortho-trifluoromethylation of acetanilides with CF3SO2Na was developed. The reaction proceeded smoothly at room temperature in air without any external photocatalyst or additive, providing the desired products in moderate to good yields with good functional group tolerance and regioselectivity.

Preparation 2-trifluoromethyl-4-substituted aniline compounds

The invention relates to a method for preparing 2-trifluoromethyl-4-substituted phenylamine and 2-trifluoromethyl-4-substituted acetanilide. The method for preparing the2-trifluoromethyl-4-substituted phenylamine and 2-trifluoromethyl-4-substituted acetanilide comprises the following main step: in the presence of sodium trifluoromethanesulfonate and tert-butyl hydroperoxide but no metal salt catalyst and under the stirring condition, maintaining a 4-substituted phenylamine compound (concrete structure shown in a formula II is described in the specification) in a reaction medium of mixture composed of dichloromethane and water at the temperature of 0-25 DEG C for 72-120 hours, so that the 2-trifluoromethyl-4-substituted phenylamine target product is obtained. The preparation method provided by the invention has potential commercial value.

Copper-free direct C-H trifluoromethylation of acetanilides with sodium trifluoromethanesulfinate

A copper-free direct C-H ortho trifluoromethylation of electron-deficient 4-substituted acetanilides using Langlois reagent (NaSO2CF3) as the CF3 source in the presence of tert-butyl hydroperoxide (tBuOOH, TBHP) was developed.

Palladium-catalyzed trifluoromethylation of aromatic C-H bond directed by an acetamino group

The first palladium-catalyzed ortho-trifluoromethylation of the aromatic C-H bond directed by an acetamino group is reported. This method provides an efficient and green approach to synthesize the highly biological potential key structure of ortho-CF3 acetanilides and anilines.

BENZIMIDAZOLE ANTIVIRAL AGENTS

Provided are compounds of Formula (I) and (II) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).

ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS

The present invention relates to compounds of Formula (I) and salts solvates and hydrates thereof. The invention further relates to pharmaceutical compositions containing said compounds and methods of treating neurological and neuropsychistric disorders using said compounds.

Tetrazolyl-phenyl acetamide glucokinase activators

Tetrazolyl-phenyl acetamides are active as glucokinase activators, and are able to increase insulin secretion, which makes them useful for treating type II diabetes.

Glycine receptor antagonists and the use thereof

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.